Jeffrey A. Morgan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey A. Morgan has a total of 302 co-authors. Here are the top co-authors by number of shared publications:
Cristina Tita
10 shared publicationsDavid E. Lanfear
10 shared publicationsGaetano Paone
Division of Cardiothoracic Surgery Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA
10 shared publicationsCeleste T. Williams
From the *Division of Cardiothoracic Surgery and †Division of Cardiovascular Medicine, Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan
8 shared publicationsHassan W. Nemeh
From the *Division of Cardiothoracic Surgery and †Division of Cardiovascular Medicine, Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan
8 shared publicationsRobert J. Brewer
From the *Division of Cardiothoracic Surgery and †Division of Cardiovascular Medicine, Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan
8 shared publications
Latest Publications
- 15 July 2017
- Published by Springer Nature
- p. 479-487
Ischemic and Hemorrhagic Stroke
- 15 July 2017
- Published by Springer Nature
- p. 545-553
Concomitant Noncardiac Surgery During Mechanical Circulatory Support: Management of Therapy
- 15 July 2017
- Published by Springer Nature
- p. 545-553
Concomitant Noncardiac Surgery During Mechanical Circulatory Support: Management of Therapy
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S36
Changes in Pulmonary Function After Left Ventricular Assist Device Implantation
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S36
Changes in Pulmonary Function After Left Ventricular Assist Device Implantation
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S33-S34
Baseline Pulmonary Function and Outcomes in Patients Receiving Left Ventricular Assist Devices
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S33-S34
Baseline Pulmonary Function and Outcomes in Patients Receiving Left Ventricular Assist Devices
- 1 June 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 61 (6) , 193S
RR11. Clinical Utility and Cost-Effectiveness of Carotid Duplex Ultrasound Prior to Cardiac Surgery
- 1 June 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 61 (6) , 193S
RR11. Clinical Utility and Cost-Effectiveness of Carotid Duplex Ultrasound Prior to Cardiac Surgery
- Open Access
- 1 November 2014
- Vol. 3 (6) , 589-594-594
Impact of reverse remodeling on cardiac function
- 1 November 2014
- Vol. 3 (6) , 589-594-594
Open AccessImpact of reverse remodeling on cardiac function
- 1 May 2014
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 60 (3) , 284-289
Stroke While on Long-Term Left Ventricular Assist Device Support
Development of stroke while on left ventricular assist device (LVAD) support can be a source of significant morbidity and mortality. From March 2006 through November 2011, one hundred patients with chronic heart failure underwent implantation of a HeartMate II (HM II) LVAD (Thoratec Corp.) as a bridge to transplant (BTT; n = 65) or destination therapy (DT; n = 35). Records were reviewed to determine the prevalence and type of postimplant stroke, anatomic cerebral location of strokes, and associated morbidity and mortality. Cox multivariate logistic regression analysis was conducted to identify independent predictors of postoperative stroke. Strokes occurred in 12 patients (12.0%): four embolic and eight hemorrhagic. Median duration of support at the time of stroke was 281.0 days for embolic strokes and 380.5 days for hemorrhagic strokes (p = 0.028). Stroke patients had a significantly higher incidence of diabetes (66.7% vs. 40.9%; p = 0.024), history of preimplant stroke (16.7% vs. 4.5%; p = 0.046), and aortic cross-clamping with cardioplegic arrest during their LVAD implant (50.0% vs. 20.2%; p = 0.034) compared with patients without postoperative strokes. Mean international normalized ratio (INR) at the time of stroke was subtherapeutic in all four patients with embolic strokes (mean: 1.5 ± 0.1 IU; range 1.3–1.6 IU) and supratherapeutic in four of eight patients with hemorrhagic strokes (mean: 3.2 ± 2.2 IU, range: 1.4–7.0 IU; p = 0.024). There was a 25.0% 30 day mortality after stroke. Diabetes (odds ratio [OR] 6.36; p = 0.029), aortic cross-clamping with cardioplegic arrest (OR 4.75; p = 0.025), duration of LVAD support (OR 1.00; p = 0.008), and INR (OR 4.42; p = 0.020) were independent predictors of stroke in multivariate analysis with a trend toward significance for history of stroke (OR 6.25; p = 0.075). Stroke represented an important source of morbidity and mortality for patients on HM II LVAD support. As long-term device therapy continues to gain popularity for both BTT and DT, a better understanding of the predictors of stroke, more strict control of postoperative anticoagulation, and the establishment of a risk stratification model may aid in minimizing its occurrence.
- 1 May 2014
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 60 (3) , 284-289
Stroke While on Long-Term Left Ventricular Assist Device Support
Development of stroke while on left ventricular assist device (LVAD) support can be a source of significant morbidity and mortality. From March 2006 through November 2011, one hundred patients with chronic heart failure underwent implantation of a HeartMate II (HM II) LVAD (Thoratec Corp.) as a bridge to transplant (BTT; n = 65) or destination therapy (DT; n = 35). Records were reviewed to determine the prevalence and type of postimplant stroke, anatomic cerebral location of strokes, and associated morbidity and mortality. Cox multivariate logistic regression analysis was conducted to identify independent predictors of postoperative stroke. Strokes occurred in 12 patients (12.0%): four embolic and eight hemorrhagic. Median duration of support at the time of stroke was 281.0 days for embolic strokes and 380.5 days for hemorrhagic strokes (p = 0.028). Stroke patients had a significantly higher incidence of diabetes (66.7% vs. 40.9%; p = 0.024), history of preimplant stroke (16.7% vs. 4.5%; p = 0.046), and aortic cross-clamping with cardioplegic arrest during their LVAD implant (50.0% vs. 20.2%; p = 0.034) compared with patients without postoperative strokes. Mean international normalized ratio (INR) at the time of stroke was subtherapeutic in all four patients with embolic strokes (mean: 1.5 ± 0.1 IU; range 1.3–1.6 IU) and supratherapeutic in four of eight patients with hemorrhagic strokes (mean: 3.2 ± 2.2 IU, range: 1.4–7.0 IU; p = 0.024). There was a 25.0% 30 day mortality after stroke. Diabetes (odds ratio [OR] 6.36; p = 0.029), aortic cross-clamping with cardioplegic arrest (OR 4.75; p = 0.025), duration of LVAD support (OR 1.00; p = 0.008), and INR (OR 4.42; p = 0.020) were independent predictors of stroke in multivariate analysis with a trend toward significance for history of stroke (OR 6.25; p = 0.075). Stroke represented an important source of morbidity and mortality for patients on HM II LVAD support. As long-term device therapy continues to gain popularity for both BTT and DT, a better understanding of the predictors of stroke, more strict control of postoperative anticoagulation, and the establishment of a risk stratification model may aid in minimizing its occurrence.
- 1 September 2013
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 59 (5) , 526-527
Pentoxifylline for the Treatment of Hemolytic Anemia in a Patient Who Developed Recurrent Gastrointestinal Bleeding While on Continuous-Flow Left Ventricular Assist Device Support
Pentoxifylline is an agent that improves red blood cell deformability (known as a hemorrheologic effect) and reduces blood viscosity. Here, we present a case of a patient with hemolytic anemia after continuous-flow left ventricular assist device (CF-LVAD) implantation that was successfully treated with pentoxifylline. Our case is a 64-year-old African American woman who was implanted with a HeartMate II device on August 6, 2010, as a bridge to transplant for end-stage heart failure. Her postoperative course was complicated by recurrent gastrointestinal bleeding and antiplatelet therapy was discontinued. On October 25, 2011, she was readmitted with anemia and hemoglobin of 6.6 mg/dl and no identifiable source of bleeding. Her lactate dehydrogenase (LDH) was 936 IU/L, indicating severe hemolysis. Due to her evidence of hemolytic anemia and her inability to tolerate antiplatelet therapy due to recurrent bleeding, she was discharged on pentoxifylline 400 mg thrice daily on October 27, 2011, with hemoglobin of 11.2 mg/dl after transfusion. After 60 days of pentoxifylline, her hemoglobin and LDH in clinic were 10.1 mg/dl and 223 IU/L, respectively. The patient was successfully bridged to transplant in June 2012. Additional analysis of pentoxifylline as a therapeutic modality to manage hemolytic anemia after CF-LVAD implantation may be warranted.
- 1 September 2013
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 59 (5) , 526-527
Pentoxifylline for the Treatment of Hemolytic Anemia in a Patient Who Developed Recurrent Gastrointestinal Bleeding While on Continuous-Flow Left Ventricular Assist Device Support
Pentoxifylline is an agent that improves red blood cell deformability (known as a hemorrheologic effect) and reduces blood viscosity. Here, we present a case of a patient with hemolytic anemia after continuous-flow left ventricular assist device (CF-LVAD) implantation that was successfully treated with pentoxifylline. Our case is a 64-year-old African American woman who was implanted with a HeartMate II device on August 6, 2010, as a bridge to transplant for end-stage heart failure. Her postoperative course was complicated by recurrent gastrointestinal bleeding and antiplatelet therapy was discontinued. On October 25, 2011, she was readmitted with anemia and hemoglobin of 6.6 mg/dl and no identifiable source of bleeding. Her lactate dehydrogenase (LDH) was 936 IU/L, indicating severe hemolysis. Due to her evidence of hemolytic anemia and her inability to tolerate antiplatelet therapy due to recurrent bleeding, she was discharged on pentoxifylline 400 mg thrice daily on October 27, 2011, with hemoglobin of 11.2 mg/dl after transfusion. After 60 days of pentoxifylline, her hemoglobin and LDH in clinic were 10.1 mg/dl and 223 IU/L, respectively. The patient was successfully bridged to transplant in June 2012. Additional analysis of pentoxifylline as a therapeutic modality to manage hemolytic anemia after CF-LVAD implantation may be warranted.
- 31 August 2013
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 19 (8) , S59
Incidence and Associated Variable Cost of Hospital Readmission during Long-Term Continuous Flow Left Ventricular Assist Device (CF-LVAD) Implantation
- 31 August 2013
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 19 (8) , S59
Incidence and Associated Variable Cost of Hospital Readmission during Long-Term Continuous Flow Left Ventricular Assist Device (CF-LVAD) Implantation
- 15 May 2013
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 28 (4) , 436-438
Chondrosarcoma Presenting as a Saddle Tumor Pulmonary Embolism
This is a case of an 18-year-old male who presented with hip pain, shortness of breath, and respiratory failure and was found to have a large saddle pulmonary embolus involving the pulmonary artery bifurcation, which extended into the main right and left pulmonary arteries, as well as the lobar branches bilaterally. The patient was taken to the operating room for an emergent pulmonary embolectomy where a significant amount of tumor was removed through an incision in the main pulmonary artery with pathology consistent with metastatic chondrosarcoma.
- 15 May 2013
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 28 (4) , 436-438
Chondrosarcoma Presenting as a Saddle Tumor Pulmonary Embolism
This is a case of an 18-year-old male who presented with hip pain, shortness of breath, and respiratory failure and was found to have a large saddle pulmonary embolus involving the pulmonary artery bifurcation, which extended into the main right and left pulmonary arteries, as well as the lobar branches bilaterally. The patient was taken to the operating room for an emergent pulmonary embolectomy where a significant amount of tumor was removed through an incision in the main pulmonary artery with pathology consistent with metastatic chondrosarcoma.